Initial public offering

Health insights from blood

On 8 March 2021, Nightingale Health Plc (“Nightingale”) has submitted the listing application to list its series B shares on Nasdaq First North Growth Market Finland, maintained by Nasdaq Helsinki Ltd.

The subscription period of Nightingale’s offering commenced on 8th March 2021. The subscription period has been discontinued on 16th of March at 6:00 p.m. for the public offering. The subscription period has ended on 18th of March at 12:00 noon for the institutional offering.

The fixed subscription price for the offer shares in the public offering is EUR 6.75 per offer share.

Important dates

8 March 2021 at 10:00 a.m. Subscription period of the offering commences
15 March 2021 at 4:00 p.m. The offering may be discontinued at the earliest
17 March 2021 at 4:00 p.m. Subscription period of the public offering ends on or about
18 March 2021 at 12:00 noon Subscription period of the institutional offering ends on or about
18 March 2021 Announcement of the final results of the offering on or about
19 March 2021 Offer shares subscribed for in the public offering registered in the investors' book-entry accounts on or about
19 March 2021 Trading in the shares commences on the First North Growth Market on or about

(Finnish time.)

Nightingale’s blood analysis detects disease risks early

Nightingale Health (“Nightingale”) offers a health data platform that detects disease risks. With our Health Data Platform, we connect the services of healthcare actors with the preventative health needs of individuals. The Health Data Platform empowers individuals to take better actions to prevent diseases by allowing them access to disease risk information.

Our mission is to bring disease prevention and healthier life within everyone’s reach. We implement our mission by assisting healthcare service providers (HSPs) in better serving their customers, by allowing people to better manage and improve their personal health, and by advancing medical scientists’ ability to do better research. We expect to benefit from the imminent global megatrend of consumers themselves wanting to manage and improve their personal health. We expect that our Health Data Platform meets this demand and provides a completely new tool to take care of health for consumers interested in managing and improving their personal health. In addition, our Health Data Platform combines the services of the healthcare actors to help consumers to improve their personal health and well-being.

The proprietary mass-scale blood analysis technology process developed by Nightingale starts with an NMR measurement of blood samples using scalable laboratory automation. The NMR measurement creates spectral data, which is further processed to concentrations of biomarkers (for example, millimoles per litre (“mmol/L”)) using AI, machine learning algorithms and state of the art software. The proprietary mass-scale blood analysis technology produces a comprehensive amount of highly accurate and repeatable biomarker results quickly, at a low cost, and on a mass scale.

Our ability to detect holistically disease risks and preventative health needs is created by combining the biomarker data produced using our proprietary mass-scale blood analysis technology and health outcome data available from biobanks.


Prospectus (in English, pdf)

Prospectus (summary in Swedish, pdf)

Marketing Brochure (in Finnish only, pdf)

Company roadshow event 8th March 2021 (webcast in Finnish with English subtitles)